1. Genetics and Genomics
  2. Human Biology and Medicine
Download icon

Epigenetic profiling of growth plate chondrocytes sheds insight into regulatory genetic variation influencing height

  1. Michael Guo
  2. Zun Liu
  3. Jessie Willen
  4. Cameron P Shaw
  5. Daniel Richard
  6. Evelyn Jagoda
  7. Andrew C Doxey
  8. Joel Hirschhorn
  9. Terence D Capellini  Is a corresponding author
  1. Broad Institute of MIT and Harvard, United States
  2. Harvard Medical School, United States
  3. Harvard University, United States
  4. University of Waterloo, Canada
Research Article
  • Cited 0
  • Views 1,725
  • Annotations
Cite as: eLife 2017;6:e29329 doi: 10.7554/eLife.29329


GWAS have identified hundreds of height-associated loci. However, determining causal mechanisms is challenging, especially since height-relevant tissues (e.g. growth plates) are difficult to study. To uncover mechanisms by which height GWAS variants function, we performed epigenetic profiling of murine femoral growth plates. The profiled open chromatin regions recapitulate known chondrocyte and skeletal biology, are enriched at height GWAS loci, particularly near differentially expressed growth plate genes, and enriched for binding motifs of transcription factors with roles in chondrocyte biology. At specific loci, our analyses identified compelling mechanisms for GWAS variants. For example, at CHSY1, we identified a candidate causal variant (rs9920291) overlapping an open chromatin region. Reporter assays demonstrated that rs9920291 shows allelic regulatory activity, and CRISPR/Cas9 targeting of human chondrocytes demonstrates that the region regulates CHSY1 expression. Thus, integrating biologically relevant epigenetic information (here, from growth plates) with genetic association results can identify biological mechanisms important for human growth.


eLife digest

Humans vary considerably in height, a trait that is partly inherited from each individual's parents. Studies have identified hundreds of small changes in DNA that contribute to differences in human height. These small changes often swap out just one of the four letters that make up the DNA code. Some changes occur within genes, yet most occur in stretches of DNA that do not contain genes. These stretches of DNA likely control whether genes important for the growth of the skeleton are switched on or off.

Cartilage cells, also known as chondrocytes, are important for height. These cells are found near the end of bones in the growth plates, where the bones grow during childhood and adolescence. The on and off switches for growth genes in chondrocytes are unknown. Identifying these genetic switches could help scientists understand how hundreds of small changes in DNA help determine how tall a person will be.

Now, Guo, Liu, Willen et al. identify thousands of switches that turn on and off genes in chondrocytes. In their experiments, chondrocytes were removed from mouse bones and a type of genetic sequencing called ATAC-seq was used to identify the stretches of DNA that act as on/off switches for genes in these cells. Further analysis revealed that many of these same on/off switches occur in human chondrocytes too. Importantly, the experiments showed that many of the small changes in DNA that contribute to differences in human height are also found within these DNA switches.

Guo, Liu, Willen et al. next tested how these switches and height-linked genes interact, and found, for example, that one switch acts to shut off the gene for a protein called chondroitin sulfate synthase 1. People with mutations in this gene can have unusually short stature. However, people with DNA changes in its nearby switch can be taller or shorter than average based on how the DNA influences the switch. More studies might help scientists understand the evolutionary significance of these DNA changes. They will also help determine if the genetic switches in chondrocytes contribute to diseases that affect the bones and joints, like bone cancer or arthritis.



Human height, a main outcome of skeletal growth, is the product of many biological and environmental interactions spanning numerous cell and tissue types acting during pre- and post-natal development. The growth plate, located at the distal ends of long bones such as the femur, is among the most important tissues influencing height. In the growth plate, condensations of mesenchymal cells differentiate into chondrocytes in the process of endochondral ossification. Chondrocytes in the growth plate reside in longitudinally oriented columns divided in zones (resting, proliferative, pre-hypertrophic, and hypertrophic) each with important functions in allowing the bone to elongate and mature (see Liu et al., 2017 and Samsa et al., 2017 for reviews) (Liu et al., 2017; Samsa et al., 2017). This process of growth plate chondrocyte differentiation and maturation promotes elongation of long bones, which ultimately determines much of human height (Baron et al., 2015). These processes are under the influence of many extrinsic and intrinsic signals (Samsa et al., 2017; Lui et al., 2012; Kronenberg, 2003).

Height has been studied for centuries as a model genetic trait, as it is easily measured and highly heritable (typically, 70–90% of variation in height within a population is attributable to genetic variation) (Silventoinen et al., 2003; Perola et al., 2007; Visscher et al., 2006; Visscher et al., 2007; Galton, 1886). Height and body proportions are likely selected and thus are interesting from an evolutionary standpoint (Turchin et al., 2012). Studies of the genetics of height can shed insight into the mechanisms of childhood growth and into developmental biology of the skeleton (Baron et al., 2015; Dauber et al., 2014). Additionally, abnormalities of growth—short stature or overgrowth—are among the most common childhood disorders and their pathophysiology is poorly understood. Thus, genetic studies of height could further our understanding of the genetic basis of skeletal disease, evolution, biology, and normal human growth and development.

Recently, genome-wide association studies (GWAS) have been used to study the genetics of height, as well as many other traits and disorders (Wood et al., 2014). This approach systematically tests each common variant in the genome for association with a phenotype of interest, such as adult height, with the goal of identifying relevant biology, either from the identities of the genes near the associated variants, or by deducing mechanism from the associated variants themselves. GWAS for height are among the largest conducted thus far (sample sizes > 250,000) and have identified more associations than any other phenotype, with nearly 700 regions of the genome (or loci) robustly associated with height (Wood et al., 2014). The finding of so many loci influencing height, with the number expected to increase with larger sample sizes, supports the assertion that height is highly polygenic. Although each of the variants at these loci have only a small effect on height (typically much less than 0.5 cm per allele) (Wood et al., 2014), the genes within the associated loci as a group highlight important mechanisms influencing growth. For example, height variants are enriched for genes implicated in numerous biological processes relevant to growth, including embryonic stem cell function, long bone development, and spine length, among a number of other processes (Wood et al., 2014). Height variants are also preferentially located near genes that are differentially expressed in the growth plate (Lui et al., 2012).

However, as with all GWAS, moving from genetic associations to biological mechanisms at any individual locus can be challenging. There are two primary reasons for this difficulty. First, there is extensive linkage disequilibrium (LD) in the human genome, meaning that the genotypes at nearby genetic variants are often tightly correlated (Gabriel et al., 2002). The consequence of LD is that at any particular locus, there will be many variants that have indistinguishable associations, and determining which variant(s) are in fact causal (rather than associated due to LD with a causal variant) remains difficult. Second, most GWAS variants (>80%) reside in non-coding regions (Gusev et al., 2014), with no nearby coding variants that can account for the associations. Non-coding variants are challenging to interpret because there is no universal regulatory code to infer function/mechanism, and these variants can act to influence gene expression at long distances and in highly tissue-specific manners (Bernstein and ENCODE Project Consortium, 2012). Various approaches have been pursued for identifying the causal variants and/or mechanisms, including overlapping associated variants with epigenetic datasets in appropriate tissues/cell-types, statistical genetic methods leveraging subtle variations in LD patterns (called ‘fine mapping’), and in vitro and in vivo functional assays (Tak and Farnham, 2015). It is also becoming increasingly clear that GWAS variants tend to fall in regions that have particular epigenetically defined states (such as enhancers or repressors) (Finucane et al., 2015; Farh et al., 2015). Thus, the overlap between GWAS and the appropriate epigenetic annotations can help refine the identities of causal variants, helping to decipher mechanism. However, epigenetic data may not exist for the biologically relevant cell type, and there is no universally successful approach to translating non-coding associations from GWAS into biological mechanisms.

Although the large number of associated variants offers advantages in making biological inferences for the set of associated variants as a whole (Lango Allen et al., 2010), defining functional mechanisms of individual height GWAS variants faces specific challenges. Height variants likely act in many tissues and stages of development, including not only the growth plate but also embryonic cells, endocrine tissues such as the pituitary, and bone, among others (Wood et al., 2014). Human growth is also a whole-organism phenotype and is less amenable to study in cell-intrinsic models, making functional approaches particularly challenging. Finally, skeletal tissues can be highly heterogeneous and challenging to isolate because in their mature form they are surrounded by a hard extracellular matrix and strongly adhering soft tissues such as tendons, ligaments, and muscles. These factors make it difficult to isolate the large numbers of biologically relevant cells that are needed for functional experiments or for traditional epigenomic assays such as ChIP-seq (Furey, 2012).

In this study, we profile the epigenetic landscape of mouse growth plate chondrocytes using a new approach called ATAC-seq (Buenrostro et al., 2015, 2013), which allows for accurate profiling of open chromatin regions using relatively few cells (~50,000). We then use the epigenetic landscape in growth plate chondrocytes to gain new insights into the mechanisms of non-coding elements in the genome influencing expression of growth plate genes. Finally, we use these epigenetic marks, in the context of statistical fine-mapping results and gene expression profiles, to better understand height GWAS variants and the mechanisms by which they may function to influence height in humans. These studies illustrate a path that can help decipher mechanism from GWAS, even when the relevant cell type is relatively inaccessible in humans.


Generation of mouse femoral growth plate epigenetic profiles

In order to identify open chromatin regions involved in long bone development, we performed ATAC-seq (Buenrostro et al., 2015, 2013) on E15.5 (Theiler Stage 23) mouse proximal and distal femoral growth zones, regions comprised predominately of the growth plate proper, the overlying perichondrium, and the cartilaginous super-structures that dictate adult bony morphology (Materials and methods). This stage of mouse embryogenesis corresponds to approximately E48-51 (Carnegie Stage 19) of human development and reflects a developmental window when the growth plate proper possesses all chondrocyte zones (resting, proliferative, pre-hypertrophic, hypertrophic zone) and is undergoing rapid cell proliferation and differentiation during endochondral ossification. Given that it remains unclear which sub-region(s) (i.e. chondrocyte zones) of the growth plate are under genetic influence to drive height variation, we performed our experiments on tissues that include all chondrocyte zones (including perichondrium) and cartilaginous tissues, excluding regions indicative of the osteogenic invasion in the developing bone collar (Figure 1a). We used ATAC-seq to isolate open chromatin regions from the DNA, which were subsequently subjected to next-generation sequencing (Materials and methods; Supplementary file 1). This approach yielded 28,257 proximal femur peaks and 27,958 distal femur peaks, with 23,764 shared peaks, 4493 peaks specific to the proximal femur, and 4194 specific to the distal femur (Figure 1b). The proximal and distal peaks span approximately 0.79% and 0.76% of the genome, respectively. We also assessed the genomic distribution of proximal and distal femur ATAC-seq peaks and found a characteristic enrichment near gene transcriptional start sites and more distal intronic and intergenic non-coding sequences (Figure 1—figure supplement 1).

Figure 1 with 2 supplements see all
ATAC-seq on in vivo collected mouse femoral growth plate zones.

(A) Pipeline of ATAC-seq on the embryonic mouse femur. Proximal (red) and distal (blue) samples were extracted from E15.5 femoral growth plates, as labeled by Col2a1 expression (insets). Tissues were harvested just proximal (red dotted lines in inset) or distal (blue dotted lines in inset) to the forming bone collar (outlined by dashed black lines). Cells were then treated to generate a single-cell suspension. Approximately 50,000 cells per sample were utilized for subsequent ATAC-seq. Open chromatin regions were then identified from the ATAC-seq data. ATAC-seq protocol adapted from Buenrostro et al. (2013). (B) Venn diagram shows the number of ATAC-seq peaks in the proximal and distal samples. (C) ATAC-seq peaks (after subtracting peaks shared in brain ATAC-seq) were analyzed for enrichment in gene sets using GREAT. Horizontal bars show enrichment p values (shown as –log10(p value)) for Human Phenotypes. The union of proximal and distal femur peaks was used.


Since a main goal was to understand the gene regulatory functions of variants influencing human height, we next mapped the locations of each mouse femur open chromatin region to the human genome (Materials and methods). Our liftover resulted in 24,805 proximal femur peaks and 24,788 distal femur peaks, representing approximately 87.7% and 88.6% of sites identified in mouse, respectively. These sites that were capable of liftover to human likely reflect relatively conserved genes involved in vertebrate musculoskeletal development (Shubin et al., 1997; Petit et al., 2017). The union of the two sets contained 25,829 peaks (Figure 1—figure supplement 1).

To determine whether ATAC-seq peaks are enriched near gene sets/pathways with specific functions, we performed an enrichment analysis using Genomic Regions Enrichment of Annotations Tool (GREAT) (McLean et al., 2010), which identifies curated gene sets enriched near epigenetic peaks. Analyses of each proximal, distal, and union femur datasets yielded general GO Biological Process and GO Molecular Processes terms related to basic cell biological processes, as well as phenotypes related to a number of biological tissues including skeletal tissues (Supplementary file 24). They also yielded phenotype terms related to general skeletal development, chondrogenesis, and long bone skeletal phenotypes, such as ‘Metaphyseal widening’, ‘Abnormality of the femoral epiphyses’, and ‘Abnormality of the femoral head’ (Figure 1c). Thus, ATAC-seq datasets generated on each specific femoral growth plate in mice reflect in part highly relevant anatomy, as well as general aspects of skeletal development in humans (see Discussion).

The ATAC-seq peaks we identified also highlight biological processes that are important in the growth plate. For example, GREAT analyses uncovered enrichment for several relevant GO Biological Processes such as ‘Cartilage condensation’, ‘Positive regulation of chondrocyte differentiation’, and ‘Chondrocyte proliferation’ (Supplementary file 24). Additionally, we illustrate ATAC-seq peaks at several well-known growth plate genes including Col2a1, Fgfr1, and Pth1r (Figure 1—figure supplement 2) (Long and Ornitz, 2013).

ATAC-seq peaks overlap other skeletal and chondrocyte epigenetic data sets

We next wanted to validate that our ATAC-seq datasets reflect open chromatin regions important to mouse chondrocyte biology. To do so, we analyzed a previous dataset that used ChIP-seq to profile Sox9 binding in mouse rib chondrocytes (Ohba et al., 2015). We found extensive overlap between Sox9-occupied sites and our open chromatin ATAC-seq peaks. For example, 86.4% of Class I Sox9 elements (i.e. elements clustering near transcriptional start sites of highly expressed non-chondrocyte-specific genes), 44.6% of Class II Sox9 elements (i.e. elements directing chondrocyte-related gene activity through direct Sox9 dimer binding), and 93.8% of Sox9 super-enhancer regions (i.e. enhancer complexes involved in chondrocyte cell identity) overlap with our femur ATAC-seq peaks (p<0.001 for all three sets, Materials and methods, Figure 2a).

Mouse proximal and distal ATAC-seq datasets capture chondrocyte biology in mouse and humans.

(A) Proportion of mouse Sox9 Class I, Class II, and super enhancer sites (Ohba et al., 2015) overlapping with ATAC-seq peaks. (B) Proportion of mouse rib chondrocyte H3K27ac, H3K36me3, H3K4me2, H3K4me3, p300, and RNA Pol II sites overlapping with ATAC-seq peaks. (C) Proportion of human embryonic limb E47 H3K27ac (Cotney et al., 2013) and human BMDC H3K27ac sites (Kundaje et al., 2015) overlapping with ATAC-seq peaks. (D) ATAC-seq peaks at the Matn3 locus. Published rib chondrocyte peaks for H3K4me2, H3K4me3, and Sox9 are shown in shades of orange. Proximal ATAC-seq peaks are shown in red, with called peaks shown as bars below. Distal ATAC-seq peaks are shown in blue, with called peaks shown as bars below. The locations of previously published chondrocyte enhancers are shown as black bars.


We also examined overlap between our dataset and various histone modifications in the mouse rib chondrocytes (Materials and methods) (Figure 2b) (Ohba et al., 2015). We found that 85.1% of RNA Pol II transcriptionally active promoters, 56.9% of H3K4me2 active promoter sites, 86.7% of H3K4me3 active promoter sites, 87.4% of H3K27ac active enhancer sites, and 59.4% of p300 histone acetyltransferase active enhancer sites overlapped with femur ATAC-seq peaks. Conversely, our ATAC-seq datasets displayed relatively lower overlap with markers of gene repression; that is, only 33.7% of H3K27me3-repressed enhancer sites overlap with femur ATAC-seq signals (Figure 2b). Based on permutation analyses, the enrichments of all these histone modification sets were significant at p<0.001. Thus, we found that femoral ATAC-seq peaks show marked evidence of active chromatin state and/or gene transcription.

We also wanted to determine if our ATAC-seq peaks reflect regulatory elements involved in human limb development and chondrocyte biology. First, we used a ChIP-seq dataset comprised of H3K27ac peaks found in E47 human limb buds (equivalent to E13.5 mouse limb buds) that are shared with mouse limb buds (Cotney et al., 2013). We found that 45.2% of these E47 human limb bud H3K27ac peaks overlapped with ATAC-seq peaks, indicating that many of our mouse femur ATAC-seq peaks reflect active human limb enhancers involved in chondrogenesis (p<0.001, Figure 2c). Second, we used an H3K27ac ChIP-seq dataset generated on human adult cultured bone marrow mesenchymal stem-cell-derived chondrocytes (BMDCs) (Herlofsen et al., 2013; Kundaje et al., 2015) and found that 13.3% of human adult BMDC H3K27ac peaks overlapped our mouse distal femur dataset (p<0.001) (Figure 2c), which indicates that our femur ATAC-seq dataset also captures cell-intrinsic properties of chondrogenesis. However, the greater overlap seen in the limb bud dataset as compared to the BMDCs suggests that our dataset may be capturing epigenetic properties present in developing in vivo tissues that are poorly modeled by cell culture systems.

Our ATAC-seq data were also able to identify 14 of 26 previously-discovered active regulatory elements residing near key cartilage genes detected at different time-points and using different assays (e.g. see Figure 2dSupplementary file 5). This suggests that mouse femoral ATAC-seq regions have in vivo enhancer activity as determined in independent assays. Overall, these data indicate that ATAC-seq datasets generated on the mouse femoral growth plates match previously expected patterns of regulatory usage important to chondrocyte biology.

Human height variants are enriched in femoral open chromatin regions

We next sought to use our ATAC-seq dataset to gain insight into height-associated variants identified by GWAS. To do so, we intersected our orthologous human ATAC-seq peaks with 688 height GWAS loci from Wood et al. (2014) (nine loci were excluded; see Materials and methods) (Wood et al., 2014). Since we do not know which variants are causal and which are associated with height due to LD, for each locus, we identified potentially causal ‘proxy’ SNPs: those with a correlation of r2 >0.5 to the lead SNP based on the European subset of 1000 Genomes Phase 3 (Auton et al., 2015). The number of proxy SNPs ranged from 1 to 3548 for each of these 688 loci (Figure 3—figure supplement 1).

Across the 688 height loci, we found that 317 loci (or ~46%) contained at least one variant that overlapped with an ATAC-seq peak. To test the significance of the observed overlap, we applied GoShifter (see Materials and methods), which performs a shuffling-based approach to evaluate the overlap between an epigenetic data set and GWAS data. We found strong enrichments for the ATAC-seq peak set and height GWAS data (p=0.0059) (Figure 3—figure supplement 1a). We repeated this analysis using the Sox9 binding and histone modifications in mouse rib chondrocytes, human BMDCs, and mouse embryonic limb datasets from above, as well as DNaseI hypersensitivity sites from mouse brain, liver, and lung (Bernstein and ENCODE Project Consortium, 2012; Ohba et al., 2015; Cotney et al., 2013; Yue et al., 2014). Only the mouse rib chondrocyte H3K4me2 peaks reached statistical significance (p=0.0237), and was far less significant than our ATAC-seq data. This suggests that our ATAC-seq data captures functional genetic variation influencing height that is not captured by the other datasets. Also, as no enrichment was observed for other mouse tissues from ENCODE, this suggests that the observed enrichment is unlikely due to artifacts stemming from our use of mouse tissues (e.g. from conserved regions being lifted over).

Figure 3 with 1 supplement see all
Height GWAS loci are enriched in ATAC-seq peaks.

(A) Enrichment of height GWAS loci in ATAC-seq peaks using GoShifter. Histogram (light blue bars) shows the number of overlaps observed in the 100,000 GoShifter permutations. Dotted line shows the number of overlaps observed in the ATAC-seq data. (B) GoShifter analysis p values for the ATAC-seq data, mouse rib chondrocyte Sox9 binding and histone modifications, human embryonic limb E47 H3K27ac, H3K27Ac of BMDCs, and brain, liver, and lung DNaseI hypersensitivity site samples from mouse ENCODE (C) Enrichment of height GWAS loci in ATAC-seq peaks using random matched GWAS loci. Histogram (light blue bars) shows the number of overlaps observed in 1000 matched random loci. Dotted line shows the number of overlaps observed in the ATAC-seq data.


To further demonstrate the specificity of our ATAC-seq peaks for capturing height GWAS signals, we repeated the GoShifter analysis by examining the enrichment of GWAS results for other complex traits/diseases at our ATAC-seq peaks. These other traits/diseases were chosen as they have no obvious connection to height and included age of menarche (Day et al., 2017), body mass index (Locke et al., 2015), coronary artery disease risk (Schunkert et al., 2011), LDL cholesterol (Teslovich et al., 2010), mean corpuscular volume (van der Harst et al., 2012), schizophrenia risk (Ripke and Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), and type 2 diabetes risk (Morris et al., 2012). These additional traits/diseases all demonstrated little to no enrichment at ATAC-seq peaks (Figure 3—figure supplement 1), suggesting that the growth plate ATAC-seq peaks are specifically capturing height/growth biology.

As a second approach to evaluate overlap between our ATAC-seq peak set and height GWAS data, we generated 1000 sets of random loci which were matched to the actual height GWAS loci based on factors including SNP density, minor allele frequency, number of proxy SNPs in the locus, and gene density (Materials and methods) (Pers et al., 2015). For each of the 1000 matched sets of random loci, we repeated the overlap with the ATAC-seq peaks. As none of the matched sets had as much overlap as our height GWAS loci, the enrichment we observed for the height GWAS data is highly significant (p<0.001; z-score: 11.88) (Figure 3c).

Notably, we observed that the actual number of SNPs that overlap an ATAC-seq peak for each set was higher than the number of represented loci. In total, there were 928 variants that overlapped with an ATAC-seq peak; these 928 variants were distributed across 317 loci (Supplementary file 6; Figure 3—figure supplement 1). This finding of more than one overlapping variant per locus may indicate multiple causal variants at each locus, as has been shown for other traits (Roman et al., 2015).

Fine-mapped height variants overlap with femoral growth plate open chromatin regions

An alternative method to narrow down potentially causal signals within GWAS loci is to use statistical fine-mapping, which leverages the association statistics and patterns of LD at each locus to identify which variants at a given locus are most likely to be causal. We applied PICS (Farh et al., 2015) to perform statistical fine-mapping of the (Wood et al., 2014) height GWAS results (Materials and methods). For each of 688 height-associated loci, we calculated credible set probabilities for all SNPs with an r2 >0.5 to the lead variant based on the European subset of 1000 Genomes Phase 3 (Auton et al., 2015). For each locus, we then determined the 95% credible set, which represents the minimum set of SNPs at that locus such that the truly causal SNP has at least a 95% probability of being in the set. Across 688 loci, this yielded a 95% credible set of 32,846 SNPs, which represents approximately a 48.2% reduction from the total number of variants in the GWAS loci. Intersecting these credible set SNPs with femur open chromatin regions revealed 468 overlapping variants spanning 192 of the 688 loci (Figure 4a).

Fine-mapping of GWAS height variants.

(left): Larger light green circle represents all height GWAS SNPs and their proxies (r2 >0.5). Smaller green circle represents the proportion of these SNPs in the PICS 95% credible set. (right) Larger light blue circle represents the 688 height GWAS loci. Medium blue circle represents 317 height GWAS loci overlapping an ATAC-seq peak. Smaller dark blue circle represents 192 loci where a PICS 95% credible set variant overlaps an ATAC-seq peak.


A subset of human height variants in femoral open chromatin regions reside near genes differentially expressed in the growth plate

A previous study profiled expression of mouse growth plate genes and identified a set of 427 genes that were differentially expressed in the growth plate (Lui et al., 2012). That study also revealed that height GWAS loci (using a previous smaller height GWAS) are enriched near differentially expressed growth plate genes (Lui et al., 2012; Lango Allen et al., 2010). We expanded on those results using the most recent height GWAS from Wood et al. (2014) and indeed found that height GWAS loci are enriched near 427 differentially expressed growth plate genes (within 100 kb) when compared to the 1000 matched random GWAS loci (p<0.001, z-score: 8.54, Figure 5a).

Height GWAS loci are enriched in differentially expressed growth plate genes.

(A) Enrichment of height GWAS loci in differentially expressed growth plate genes. Dotted line shows number of GWAS loci with a nearby differentially expressed growth plate gene (±100 kb). Histogram (light blue bars) shows the number of overlaps observed in 1000 matched random loci. (B) Enrichment of height GWAS loci in differentially expressed growth plate genes and ATAC-seq peaks. Same as (A), except showing overlap for GWAS loci overlapping differentially expressed growth plate gene (±100 kb) and ATAC-seq peak.


Since we detected enrichment of height GWAS variants near femoral open chromatin regions (see Figure 3) and reasoned that many of the variants likely function by influencing expression of growth plate genes, we next identified the number of GWAS variants that fit the criteria of residing in an open chromatin region near a differentially expressed gene (within 100 kb). We again used the 688 GWAS loci from Wood et al. (2014) and their proxy SNPs (r2 >0.5) and found that 46/688 loci (or ~6.7%) contained at least one GWAS variant that overlapped with an ATAC-seq peak and resided near a differentially expressed gene (Supplementary file 6). Using the same 1000 sets of matched random loci as described above, we found that these overlaps were highly significant (p<0.001, z-score: 6.36, Figure 5b). These loci likely represent combinations of functional variants that overlap an epigenomic element in growth plates that then modulates expression of nearby genes influencing height.

Wood et al., had previously observed that height GWAS SNPs that represent cis eQTLs in whole blood are enriched for expression in cartilage (Wood et al., 2014). Here, we sought to evaluate whether differentially expressed growth plate genes that are also eQTLs genes in whole blood are enriched at ATAC-seq peaks. Among the 427 differentially expressed growth plate genes, 157 had previously been identified as eQTL genes in whole blood (Westra et al., 2013). Using the GoShifter permutation analysis as described above, we demonstrated that the corresponding eQTL variants for these 157 genes are significantly enriched at ATAC-seq peaks (p=0.0004)

Of the 46 loci in the ATAC-seq femur comparison that fall near genes differentially expressed in growth plates, 44 different genes have been identified as possibly being modulated by these putative regulatory variants (note, some genomic loci have multiple genes and/or GWAS loci) (Supplementary file 6). These genes represent major signaling molecules (e.g. IHH, HHIP), transcription factors (e.g. RUNX2), extracellular matrix factors (e.g. CHSY1, EXTL1), among other factors involved in the growth plate in both humans and mice.

Known and novel targets of human height variants in putative chondrocyte regulatory regions

We next examined some of the most compelling loci from a genetic and mechanistic perspective. We filtered for loci where a height GWAS variant in the PICS 95% credible set overlapped an ATAC-seq peak, and was near a differentially expressed growth plate gene (±100 kb). In total, 59 variants distributed across 26 loci met these criteria. These 59 variants thus have strong evidence for being potentially causal variants and might be prioritized for downstream study (Supplementary file 6).

For example, at the CHSY1 locus, four variants (rs8042551, rs11639408, rs9920291, and rs3911964) met these criteria. Disruption of Chsy1 in mice and humans leads to severe skeletal phenotypes including long bone length reductions (Wilson et al., 2012; Temtamy et al., 1998; Tian et al., 2010; Li et al., 2010). Of the four variants, rs9920291 is predicted to alter HOXD13 binding, as suggested by data generated using universal protein binding microarray technology that demonstrates that the eight base-pair sequence matching the immediate rs9920291 locus disrupts in vitro binding by HOXD13 (Figure 6a, Supplementary file 7), a homeodomain transcription factor that is expressed in the growth plate (Kuss et al., 2014; Reno et al., 2016) and has known activating and repressive roles in skeletal development (Johnson and Tabin, 1997). We performed a series of functional assays to test the effects of allelic variation at rs9920921. First, using a luciferase reporter assay in T/C-28a2 human chondrocytes, we found that the open chromatin region surrounding rs9920291 acts as a repressor of expression (p=7.83×10−6 and 3.6 × 10−4 for variants carrying the reference and alternate alleles respectively) (Figure 6b). In addition, the alternate T allele, (i.e. the height-increasing allele of rs9920291) makes the regulatory element act as a weaker repressor (p=0.0014). This is consistent with data from GTEx (Lonsdale J, GTEx Consortium, 2013), where rs9920291 acts as an eQTL for CHSY1 in transformed fibroblasts (p=1.0×10-7; Figure 6—figure supplement 1), with the T allele correlating with increased CHSY1 expression levels. Additionally, we leveraged the fact that in HEK-293FT cells, rs9920291 is heterozygous, along with several additional SNPs in the coding region of CHSY1. Assaying a heterozygous exonic coding SNP (rs28364839) and a 3’UTR SNP (rs11433), we demonstrate that rs9920291 displays allelic skew in expression (p<0.001 for both assayed variants; Figure 6d).

Figure 6 with 2 supplements see all
Intersections of GWAS height variants with ATAC-seq data identify novel putatively causal variants.

(A) ATAC-seq height GWAS variant intersections at the CHSY1 locus refine height GWAS loci to fewer putatively causal variants. Height GWAS SNPs (r2 >0.5 to lead SNP) are shown as black bars, and SNPs in the PICS 95% credible set are shown as red bars. Published H3K27ac ChIP-seq in E47 human limb buds and BMDCs are shown in orange and purple respectively. ATAC-seq peaks lifted over to human are shown for proximal femur (red) and distal femur (blue). Published Sox9 class II sites from mouse rib chondrocytes lifted over to human are shown in light blue. Four height SNPs overlap an ATAC-seq peaks, representing putatively causal variants. Of these four variants, rs9920291, a C to T substitution, significantly alters the predicted binding of HOXD13 (UniProbe: HOXD13 C allele z-score = 0.7825; HOXD13 T allele z-score = 5.1269 (also Supplementary file 7) (B) Results of a luciferase reporter assay. A 341 bp region surrounding rs9920291 and containing either the reference or alternate allele at rs9920291 was cloned into a luciferase reporter vector and transfected into the human chondrocyte cell line T/C-28a2. Expression was normalized (to 1.0) by luciferase activity of the empty vector luciferase construct. (C) Allelic skew of two CHSY1 genic variants (rs28364839 which is exonic and rs11433 which is in the 3’UTR) in HEK-293FT cells. Notably, HEK-293FT is heterozygous for rs9920291, along with both assayed variants. (D) Expression of CHSY1 following CRISPR-Cas9-mediated deletion of regions surrounding rs9920291 (see Figure 6—figure supplement 1) in T/C-28a2 chondrocyte cell lines (N = 3 biological replicates). CHSY1 expression following deletion of an approximate 135 bp region using guides 1 and 4 is shown in purple and expression following deletion of an approximate 17 bp region using guides 6 and 8 is shown in orange. Expression values are normalized to a control CRISPR-Cas9 vector (green). (E) CHSY1 expression following HOXD13 overexpression in T/C-28a2 cells (N = 3 biological replicates) (see also Figure 6—figure supplement 1). Expression is normalized by an empty overexpression vector. ***p<0.001 by unpaired t-test.


To further demonstrate that the region surrounding rs9920291 displays regulatory activity for CHSY1, we performed CRISPR-Cas9 targeting of a 135 bp sequence spanning a conserved portion of the regulatory element containing rs9920291 (guides sg1 and sg4), or an 17 bp sequence immediately surrounding rs9920291 (guides sg6 and sg8). Either deletion led to a significant upregulation of CHSY1 expression in vitro in T/C-28a2 cells (p=7.83×10−6 for the 135 bp deletion and p=3.64×10−4 for the 17 bp deletion; Figure 6d), confirming the regulatory element’s repressor activity. Consistent with our computational predictions that rs9920291 perturbs HOXD13 binding, we found that overexpression of HOXD13 in T/C-28a2 cells significantly upregulated CHSY1 expression (p=1.63×10−5; Figure 6e,Figure 6—figure supplement 1).

We also highlight a previously identified height-associated variant (rs4911178) at the GDF5 locus, which resides in an ATAC-seq peak active in femoral growth plates (Figure 6—figure supplement 2). We have shown in separate work that the underlying enhancer drives GDF5 expression in growth plates and that rs4911178 has allele-specific activity(Capellini et al., 2017). Thus, our approach of integrating genetic and growth plate epigenetic data has the ability to identify previously discovered cis-regulatory targets that mediate human height variation.

Motif analysis of height variants that reside within distal femur ATAC-seq peaks

To expand upon our understanding of transcription factor binding at ATAC-seq open chromatin regions, we performed a series of motif enrichment analyses using HOMER (see Materials and methods). First, we performed a de novo motif analysis on the union of distal and proximal femoral ATAC-seq peaks in mouse to identify enriched transcription-factor-binding motifs. We identified a number of highly enriched motifs relevant to chondrogenesis and other skeletal developmental processes, including Atf3 (James et al., 2006), Msx2 (Amano et al., 2008), Pbx1 (Selleri et al., 2001), and Ctcf (Jerković et al., 2017) (Figure 7a, Supplementary file 8, sheet 1). We performed a similar analysis on the liftover human ATAC-seq regions and found enrichments for a similar set of motifs (Figure 7a, Supplementary file 8, sheet 2).

Motif disruption by height GWAS variants intersecting ATAC-seq peaks.

(A) Selected enriched motifs within mouse femoral ATAC-seq open chromatin regions. These motifs were also found following liftover of the peaks to the human genome (see Supplementary file 8, sheets 1 and 2). (B) Histogram showing distribution of log-odds motif scores of CTCF-disruption for height GWAS variants within ATAC-seq regions. Negative values indicate a disruptive effect of the variant while positive values indicate a 'conservation' of the motif hit by the variant. (C) Histogram of number of variants predicted to disrupt CTCF motifs within random subsamples of variants. Dotted line indicates number of CTCF-disrupting variants observed in the height GWAS variants overlapping ATAC-seq regions (n = 78, p<0.01). (D) An example of a variant (rs12529733) that overlaps ATAC-seq peaks and is predicted to alter CTCF binding. Features in the figure are the same as described in Figure 6A.


We next characterized the effect of height GWAS variants that intersect with these motifs within ATAC-seq peaks. Further characterization of the GWAS variants within CTCF motifs indicated a tendency toward disruptive effects (Figure 7b). Comparing the height GWAS variants intersecting ATAC-seq peaks to 500 sets of random GWAS variants revealed an enrichment for variants that are predicted to impact CTCF-binding (p<0.01, z-score: 6.01, Figure 7c) (see Materials and methods). An example of a variant within a CTCF motif is shown in Figure 7d. Additionally, we detected a strong enrichment of height GWAS variants overlapping predicted PBX1 motifs within ATAC-seq regions, when compared to height GWAS variants across the genome (adjusted p value=1.91×10−108, Supplementary file 9; see Materials and methods).


Like many anthropometric traits, height is highly heritable and influenced by a large number of distinct genetic inputs that influence the development and/or growth of a number of tissues (Visscher et al., 2010). Of these tissues, the growth plate plays a key role in determining overall height. Despite decades of research on chondrocyte growth plate biology, we have been limited in our understanding of how height GWAS variants—most of which are non-coding—act in the growth plate to influence height. This is due in part to the paucity of epigenetic data related to the regulatory landscape of the growth plate, as these datasets have been technically challenging to generate. Here, we leveraged a new method (ATAC-seq) (Buenrostro et al., 2015, 2013) to overcome previous technical challenges and reveal the open chromatin regulatory landscape of growth plate chondrocytes. We then analyzed height GWAS data in the context of the femur growth plate epigenetic landscape to gain insight into how height GWAS variants act at the growth plate.

Our analyses revealed that ATAC-seq datasets generated from mouse growth plate chondrocytes overlap previously identified signals of chondrocyte biology in the mouse, as well as in humans. The ATAC-seq peaks reside near genes enriched for human phenotypes related to skeletal biology, such as ‘metaphyseal widening.’ These peaks also reside near genes with known roles in chondrocyte biology and include biological processes such as ‘cartilage condensation’ and ‘chondrocyte proliferation.’ We also show that our open chromatin profiles overlap quite faithfully with locations of active regulatory enhancers and Sox9-binding sites as assessed using ChIP-seq on mouse rib chondrocytes (Ohba et al., 2015). Additionally, our datasets overlap with evidence of regulatory control during chondrogenesis and human limb embryogenesis (Cotney et al., 2013; Herlofsen et al., 2013; Kundaje et al., 2015). These findings indicate that general aspects of chondrocyte regulation, in part shared between humans and mice, are captured by our ATAC-seq growth plate datasets. While we note that appropriate human datasets generated from growth plate chondrocytes are still unavailable and that there is evidence of substantial functional divergence in the genic and non-coding usage in cell types between species (Bernstein and ENCODE Project Consortium, 2012), the strong overlap between our mouse ATAC-seq data and human embryonic limb and human BMDCs suggests considerable conservation in the regulatory profiles at the growth plate.

While our datasets capture aspects of general chondrocyte biology, we also found that ATAC-seq peaks acquired on femoral tissues show enrichment in human phenotypes related to the anatomy of femur. This finding points to a fine-grained, modularized control of skeletal element-specific biology. This is also supported by our independent identification of a number of previously published long bone growth plate chondrocyte enhancers in mice and humans, as well as the growing evidence that a number of important skeletal development genes, such as Bmp5 (Guenther et al., 2015), Gdf6 (Mortlock et al., 2003; Indjeian et al., 2016), and Gdf5 (Capellini et al., 2017; Chen et al., 2016) have conserved modularized cis-regulatory architectures. As height is encoded by a number of genetic inputs, undoubtedly variants that influence general, as well as element-specific regulatory enhancers (e.g. tibia versus femur), will be important factors shaping height variation in humans.

Given that over 80% of GWAS height loci are non-coding, our study demonstrates that height GWAS variants are significantly enriched in growth plate chondrocyte regulatory regions and that the majority reside in intergenic portions of the genome. Importantly, this enrichment of height GWAS loci was not observed nearly as strongly in other chondrocyte or limb bud tissues, which suggests that our dataset is capturing functional genetic variation influencing height that is not captured by other existing datasets. No enrichment was observed for DNaseI hypersensitivity sites from mouse brain, liver, or lung, which suggests that our enrichment with height GWAS variants is tissue-specific and also not due to an artifact from the liftover process from mouse to human. These ATAC-seq peaks overlapping height GWAS variants are enriched for nearby differentially expressed growth plate genes. GWAS results for other traits/diseases that are not clearly related to growth/height did not show enrichment at the ATAC-seq peaks, demonstrating that the ATAC-seq peaks are specifically capturing growth/height biology. Finally, our motif analysis additionally revealed that a number of these human height variants may alter the binding of transcription factors with important roles in chondrogenesis and gene regulatory processes.

Combining our statistical fine-mapping and functional fine-mapping has allowed us to narrow down to a much smaller subset of putatively causal variants for downstream functional testing. As an example, one putatively causal variant (rs9920291) resides in the Chondroitin Sulfate Synthase 1 (CHSY1) locus. Human mutations in CHSY1 result in Temtamy preaxial brachydactyly syndrome, characterized by short stature, preaxial brachydactyly, and hyperphalangism of digits 1–3 (45, 46), as well as a number of additional soft and hard tissue disorders. rs9920291 is in the fine-mapped credible set, resides in regulatory elements active in human adult chondrocytes and embryonic limb tissues, and displays evidence of binding by Sox9 in mouse chondrocytes. rs9920291 additionally modifies a critical nucleotide (C to T) and disrupts the experimentally determined in vitro binding motif of HOXD13, a homeodomain transcription factor that is expressed in chondrocytes (Kuss et al., 2014; Reno et al., 2016) and has known roles in skeletal development (Johnson and Tabin, 1997). We performed extensive experimental characterization of rs9920291 at the CHSY1 locus. We demonstrated that rs9920291 displays allelic regulatory activity in human chondrocyte cell lines. We also deleted the regulatory region surrounding rs9920291 using CRISPR-Cas9 and demonstrated that these deletions alter CHSY1 expression. Thus, our results elucidate how common regulatory variation at this locus influences height by modulating CHSY1 expression. Height, given that it is generally not a cell-intrinsic phenotype, has traditionally not been conducive to functional experimentation. Our results highlight how we can pinpoint likely causal variants and mechanisms to make experimentation more tractable for a challenging phenotype such as height. To our knowledge, along with GDF5, this is the only other height GWAS locus with functional validation (Capellini et al., 2017).

A number of other variants, listed in the browsable Supplementary file 6, are available for functional testing. When more extensive height GWAS data (ideally imputed to a dense reference panel) are generated and more sophisticated fine-mapping methods are developed, additional evidence of enrichment for fine-mapped variants may be revealed using our approach. When these experiments are combined with high-throughput functional assays to test variant functionality, a more refined picture of height biology will emerge.

Materials and methods

ATAC-seq methods

All experiments were performed following protocols approved by the Harvard University IACUC committee. Timed matings were established between FVB mice, and pregnant females were euthanized at E15.5 in order to acquire embryonic long bone growth plates. Embryos were dissected in PBS1X on ice under a dissection scope and the proximal and distal growth zones of the right and left femur were stripped clear of soft tissues. Each proximal or distal cartilaginous end was then micro-dissected from the bony diaphysis (Figure 1) and separately pooled from a single litter, consisting on average of eight animals. Two biological replicates were collected in line with previous ATAC-seq studies (Gehrke et al., 2015). The samples were collected in micro-centrifuge tubes containing 200 ul 5% FBS/DMEM. To generate a single-cell chondrocyte suspension, each pooled sample was then subjected to 1% Collagenase II (VWR 80056–222, Radnor, Pennsylavania) digestion for 2 hr at 37°C rocking, mixing every 30 min. After placing on ice, samples were filtered using a micro-centrifuge filter set-up by gently mashing the residual tissues through the filter followed by rinsing with 5% FBS/DMEM. Samples were then spun down at 500 g at 4°C for 5 min. We next performed cell counting methods using trypan blue and a hemocytometer and performed subsequent ATAC-seq steps on those samples that had cell death rates well below 25%. On average we acquired 500,000–1,000,000 living cells per harvest. Next, cells were re-suspended in concentrations of 50,000 cells in 1x PBS. Cell samples then subjected to the ATAC-seq protocol as described in Buenrostro et al., 2015Buenrostro et al., 2015, modifying the protocol by using 2 µl of transposase per reaction. The transposase reaction product was then purified using the Omega MicroElute DNA Clean Up Kit following manufacturers protocols, eluted in 10 µl of warmed ddH20, and stored at −20°C.

Next, samples were subjected to PCR amplification and barcoding following Buenrostro et al., 2015Buenrostro et al., 2015. All primers used in this step are listed in Supplementary file 1. Ten microliters of transposed DNA were then placed in a reaction containing NEBNext High-Fidelity PCR Master Mix, ddH20, and primers. After amplification, samples were transferred to micro-centrifuge tubes and subjected to the OMEGA Bead Purification Protocol following manufacturers protocol. The samples were eluted in 30 µl of TE, run on a nanodrop, diluted to 5 ng/µl and run on a bioanalyzer. Prior to sequencing sample concentrations were determined using the KAPA Library Quantification Complete Kit (KK4824). Samples were then sent out to the Harvard University Bauer Core Facility for sequencing on one lane of the Illumina NextSeq 500 (see Supplementary file 1).

Sequencing yielded approximately 400 million reads per lane and an average of 100 million per sample. Quality control statistics are presented in Supplementary file 1. Sequenced reads were next aligned to the mouse reference mm10 genome assembly using Bowtie2 (Langmead and Salzberg, 2012). Duplicated reads were removed and significant peaks determined by using MACS2 software (version 2.1.0) (Johnson and Tabin, 1997). Peaks were assessed for reproducibility between biological replicates using the IDR statistical test (Li et al., 2011) at various statistical cut-offs, with an IDR threshold of <0.05 selected to define reproducible peaks for all subsequent analyses. Datasets for other IDR score thresholds are available upon request and when used in all analyses show similar statistical enrichments. Intersections between proximal and distal femur peaks were done with IDR-filtered narrow peak files, with the proximal/distal-common set generated by merging overlapping peaks. Annotations of the narrow peak files generated on all datasets were made using HOMER annotatePeaks.pl (http://homer.salk.edu/homer/motif/).

Raw sequencing fastq files and processed peak bed files have been deposited on NCBI GEO (GSE100585).

GREAT analyses

GREAT (Genomic Regions Enrichment of Annotations Tool) (McLean et al., 2010) identifies curated gene sets that display enrichment near regulatory elements. The software first identifies likely target genes of each regulatory element based on distance. GREAT then tests the enrichment of these genes localized near regulatory elements in curated gene sets that reflect pathways and molecular processes. To increase the specificity of our results, we removed peaks that were also seen in ATAC-seq from the mouse brain. ATAC-seq results were then lifted over to hg19 for analysis. We used the ‘Significant By Region-based Binomial view’; otherwise, all default input parameters and output display settings available at the GREAT website (http://great.stanford.edu/) were used. GREAT v3.0.0 was used.

Additional epigenetic datasets

Mouse chondrocyte data: ChIP-seq profiles Sox9 binding in mouse rib chondrocytes was obtained from Ohba et al. (2015). We also obtained ChIP-seq of RNA Pol II, H3K4me2, H3K4me3, H3K27ac, p300 and H3K27me3 in mouse chondrocytes from Ohba et al. (2015).

Human data: H3K27ac ChIP-seq of E47 human limb buds that are shared with mouse was obtained from Cotney et al., 2013 (Cotney et al., 2013). H3K27ac ChIP-seq of human adult cultured BMDCs was obtained from http://egg2.wustl.edu/roadmap/web_portal/processed_data.html (Herlofsen et al., 2013; Kundaje et al., 2015). The consolidated epigenome BroadPeak file was used.

Mouse ENCODE data: DNA-seq data were downloaded from the mouse ENCODE project (Yue et al., 2014). All samples were from Mus musculus C57BL/6 and included brain male embryo (14.5 days) (ENCSR000COE), liver male adult (8 weeks) (ENCSR000CNI), and lung male adult (8 weeks) (ENCSR000CNM). Processed NarrowPeak bed files were downloaded for each tissue and then lifted over to hg19 as described above.

Epigenetic intersection analyses

All intersection analyses of ATAC-seq peaks with GWAS loci, genes, or ChIP-seq peaks were performed using BEDTools v2.18 (Quinlan and Hall, 2010) and custom R scripts (R version 3.1.1) (see Source code 1). For overlaps of genes with GWAS loci, an overlap was called for a given height GWAS locus if the gene’s transcriptional boundaries were within 100 kb of any SNP in the locus (defined as r2 >0.5 to lead SNP).

For overlap of ChIP-seq datasets, any overlap (>=1 bp) was considered to represent the same feature. To evaluate the significance of overlap, a permutation-based procedure was implemented in the R package regioneR (Gel et al., 2016). We used the ‘circularRandomizeRegions’ function to generate random permutations. In this function, each chromosome is ‘circularized’, and the peaks bed file is shifted at random along the circularized chromosome and evaluated for overlap. We used 1000 permutations to calculate the empiric p value.

GoShifter analysis

GoShifter v0.2 was used to evaluate the statistical enrichment of the overlap between height GWAS loci and ATAC-seq peaks (or other epigenetic peaks) (Trynka et al., 2015). The European (EUR) subset of 1000 Genomes Phase 3 (Auton et al., 2015) was used to identify proxy SNPs and calculate LD. An LD cutoff of r2 >0.5 to the index SNP was used. A window size of 100 kb was used to find LD SNPs (‘window’ option). All other parameters were set to the software default. 100,000 permutations were run. GoShifter analyses for additional traits/diseases were performed in the same fashion.

Generation of matched GWAS loci

SNPSNAP (Pers et al., 2015) was used to generate matched loci for the height GWAS loci. The European (EUR) subset of 1000 Genomes Phase 3 (Auton et al., 2015) was used to identify proxy SNPs and calculate LD. Loci were defined as variants with r2 > 0.5 to the index SNP. Loci were matched using default criteria: MAF ± 5%, gene density ± 50%, distance to nearest gene ±50% and LD buddies ± 50%. SNPSNAP was able to generate matched gene sets for 676 out of the 697 loci from Wood et al. (2014). 1000 matched sets of random GWAS loci were generated.

Differentially expressed growth plate genes

A list of 427 differentially expressed mouse genes was downloaded from Lui et al. (2012). These 427 differentially expressed genes were determined in the Lui et al. (2012) paper based on meeting two of three criteria: (1) spatial regulation in the growth plate, (2) temporal regulation during growth plate formation, and/or (3) specific expression in the growth plate (as compared to other tissues such as the lung, kidney, heart). Orthologous human genes and their respective positions were identified using Ensembl Biomart (Kinsella et al., 2011). The ‘Ensembl Genes 86’ database was used.

eQTL overlap analysis

Using the set of 427 differentially expressed growth plate genes (see above), we identified 157 genes that were also genes for cis-eQTLs in whole blood (FDR < 0.05) as identified by Westra et al. (2013). For each of these 157 eQTL genes, the corresponding eQTL variant with the strongest p value was used. Using this set of eQTL variants, GoShifter was run as described above to test for enrichment at ATAC-seq peaks.

GTEx data

The Genotype-Tissue Expression (GTEx) Project (Lonsdale J, GTEx Consortium, 2013) was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 10/27/2017.

Motif analysis

ATAC-seq peak centers from proximal/distal tissues were aggregated and padded outwards to a fixed length of 200 bp (based on the distribution of ATAC-seq peak sizes). HOMER (Jerković et al., 2017) de novo motif analysis was performed for the sequence set utilizing a 10x random shuffling as a background set. De novo motifs were compared to a vertebrate motif library provided by HOMER, which includes the JASPAR database (Visscher et al., 2010), with matches scored using Pearson’s correlation coefficient of vectorized motif matrices, with neutral frequencies (0.25) substituted for non-overlapping positions.

Lifted over human ATAC-seq peaks were then intersected with height GWAS variants from Wood et al. (2014). Variants were characterized for selected motifs which appeared in both the mm10 and hg19 de novo motifs using motifbreakR (Coetzee et al., 2015). Motif matches were scored using log-odds scoring (with 0.25 A/C/G/T background frequencies) for both reference and mutated sequences. Effects on position-weighted matrix (PWM) scoring were calculated as differences between the log-odds score of reference and mutant motif hits, with negative differences representing a disrupted motif. To assess enrichment for CTCF-disrupting variants in the ATAC-intersected variant set, 500 randomly sampled subsets (n = 928) of the height GWAS variants (excluding those intersecting ATAC-seq peaks) were generated and counted for CTCF-disrupting variants. Counts were standardized and statistical significance was assessed using a continuous distribution function of the standard normal distribution.

To assess enrichment of predicted transcription factor binding near variants intersecting ATAC-seq peaks, a set of hg19 DNA sequences was first constructed using 30 bp windows centered on each variant, generating an ATAC-intersected subset and whole GWAS superset. A utility from HOMER (findmotifs.pl) was then used to scan this sequence set using its provided vertebrate motif library to search for motif hits. Motifs from JASPAR 2016 were filtered (386 motifs) and counted within each of the two sets. Hypergeometric tests were performed for all motifs using Benjamini-Hochberg FDR correction (Benjamini and Hochberg, 1995).

Expression plasmids

CRISPR-Cas9 PX458 vector was obtained from Addgene (Cambridge, Massachusetts). pGL4.23 luciferase and pGL4.74 renilla vectors were acquired from Promega (Madison, Wisconsin). Plasmids encoding HOXD13-FLAG and HOXD13-HA were generously gifted from Dr. Vincenzo Zappavigna (University of Modena and Reggio Emilia) (Caronia et al., 2003).

Cell lines and culture conditions

Human embryonic kidney (HEK-293FT) cells were acquired from Dr. Pardis Sabeti (Harvard University and Broad Institute). T/C-28a2 human chondrocyte cells were acquired from Dr. Li Zeng (Tufts University) courtesy of Dr. Mary Goldring (The Hospital for Special Surgery). Both cell lines were cultured at 5% CO2 at 37°C in Dulbecco's Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin (P/S). Media was replaced every 2–3 days and the cells were sub-cultured every 5 days.

CRISPR-Cas9 targeting at the CHSY1 regulatory element

All guide RNAs surrounding the human CHSY1 regulatory element or rs9920291 were designed using MIT CRISPR Tools (http://crispr.mit.edu), synthesized by Integrated DNA Technologies, Inc (Coralville, Iowa), and cloned into the PX458 vector following published protocols (Ran et al., 2013). The sequence of all sgRNAs are listed in Supplementary file 10 and their locations with respect to the targeted CHSY1 regulatory element and rs9920291 are found in Figure 6—figure supplement 1. Guide RNAs were initially tested for ability to induce efficient deletions of the human element in cultured HEK-293FT cells. After two days of culture at 37°C, transfected HEK-293FT cells were examined under a GFP-microscope to verify successful transfection and GFP expression. DNA was then extracted using E.Z.N.A Tissue DNA Kit, and the CHSY1 regulatory element region was amplified using PCR and primers surrounding the guide RNA design sites (Primers: ‘rs9920291 Forward’ and ‘rs9920291 Reverse’, Supplementary file 10). Amplification products were isolated from 1% agarose gels (E.Z.N.A Gel Extraction Kit) and Sanger sequenced to verify deletions of various sizes (see below).

After confirmation that sgRNAs worked in HEK-293FT cells, we performed in vitro deletion in the T/C-28a2 chondrocyte cell line (Kokenyesi et al., 2000; Finger et al., 2003). The same sgRNAs were used as above. T/C-28a2 cells were maintained in DMEM (Gibco, Gaithersburg, Maryland) supplied with 10% FBS (Gibco) and 1% Pen/Strep (0.025%), and seeded in a six-well plate 1 day prior to transfection. After culturing at 37°C, we scanned cells under a GFP-microscope to verify successful transfection efficiency (i.e.,>70% of cells) and GFP expression (N = 3). DNA was then extracted using E.Z.N.A Tissue DNA Kit, and the CHSY1 regulatory element region was amplified using PCR primers surrounding the guide RNA design sites (MiSeq Primers Forward and MiSeq Primers Reverse, Supplementary file 10). Amplification products were isolated from 1% agarose gels (E.Z.N.A Gel Extraction Kit). Mi-Seq sequencing at the MGH CCIB DNA Core was used to verify successful targeting of the larger CHSY1 regulatory region (hg19: chr15:101,749,730-101,749,865) with a modification efficiency of approximately 10% and smaller CHSY1 regulatory region around rs9920291 (hg19: chr15:101,749,797–101,749,813) with a modification efficiency of approximately 8.5%. RNA was also extracted from control and CRISPR-Cas9 targeted T/C-28a2 cells. RNA was DNase-treated and converted to cDNA for qPCR (see below).

cDNA synthesis and qRT-PCR analysis

Total RNA was extracted from HEK-293FT and T/C-28a2 cells and prepared using the Trizol Reagent (Thermo Fisher Scientific, Springfield Township, New Jersey) and Direct-zolTM RNA Miniprep kit (ZYMO). Three micrograms of total RNA were used to synthesize first-strand cDNA using SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific). qRT-PCR analysis was then performed with specific primers and Applied Biosystems Power SYBR master mix (Thermo Fisher Scientific) with GAPDH as a reference gene. Primers used for qRT-PCR are listed in Supplementary file 10.

Cloning, construct preparation, in vitro luciferase reporter and overexpression assays

Prior to in vitro transfection of CHSY1 regulatory sequences into HEK-293FT and T/C-28a2 cells (see below), primers containing KpnI/HindIII linker sequences were used to amplify the putative regulatory element surrounding rs9920291. (see above and Supplementary file 10). The PCR protocol was initiated at 98°C for 30 s, followed by 34 cycles at 98°C for 20 s, 60°C for 20 s, and 72°C for 30 s, and then followed by a 72°C for 5 min final extension. Coriell (Camden, New Jersey) sample NA12286 was used to amplify the region containing the reference allele of rs9920291 and NA19119 was used to amplify the region containing the variant allele of rs9920291. Each amplicon was then ligated into a KpnI/HindIII containing pGL4.23 firefly luciferase vector using NEBuffer 2.1 (NEB B7202S) for digestion and T4 DNA Ligase (NEB M0202S) for ligation according to manufacturer's protocols (New England Biolabs, Beverly, Massachusetts). Ligates for constructs containing inserted or non-inserted (‘empty’) sequence were next transformed into DH10B cells, and streaked on ampicillin plates. Single colonies were then picked, PCR screened, sequenced, and purified using E.Z.N.A. Endo-Free Plasmid DNA Maxi Kits (Omega D6926-03). The PCR protocol used for screening is listed above. Sanger sequencing was used to confirm the orientation as well as sequence identity of each insert as well as the entire pGL4.23 firefly vector. pGL4.74 renilla vector was similarly transformed, amplified, purified and sequence verified. Prior to HOXD13 over-expression experiments, HOXD13 constructs were transformed into DH10B cells, streaked on ampicillin plates, individual colonies were grown and purified via Endo-Free Plasmid DNA Maxi Kits (Omega D6926-03). Purified plasmids underwent diagnostic digest and sequence verification.

HEK-293FT cells and T/C-28a2 chondrocytes were passaged using standard conditions (see above) prior to reporter gene transfection and HOXD13 over-expression experiments. Prior to transfection, cells were first cultured in DMEM with 10% FBS for 24 hr in 96-well dishes at a seeding density of 3 × 104 cells/well. The volume of media per well was then brought to 100 µl. For luciferase reporter experiments, cells were then transiently transfected with 100 ng firefly luciferase reporter vector or empty pGL4.23 luciferase vector, along with 5ng pGL4.74 renilla vector. Transfections were performed using Lipofectamine 2000 (Invitrogen 11668–019) at a Lipofectamine:DNA ratio of 4:1 according to manufacturer instructions. Luciferase activity was measured 48 hr after transfection using the 96-welll Dual-Glo Luciferase Assay System (Promega E2940) following manufacturer protocols on a SpectraMax L Microplate Reader (Molecular Devices; Cat# SpectraMax L Config) with a 1 min dark adapt, 5 s integration, and max range settings. For cell culture experiments, to compare expression between the reference and alternate allele CHSY1 constructs (Figure 6b), we performed at least four independent transfection experiments at each concentration containing eight technical replicates (i.e. individual wells of a 96-well plate) per construct. We first normalized each firefly luciferase value per well by its corresponding renilla luciferase value per well, and then compared the mean expression of the reference allele construct (normalized by empty vector) to that of the mean expression of the alternate allele construct (normalized by empty vector) using a two-sample directional Student's t-test. For HOXD13 overexpression experiments, HEK-293FT and T/C-28a2 cells were transfected as above but with 0, 2 and 4 µg of HOXD13 expression or control constructs (N = 3 biological replicates per condition), and after 24, 48, and 72 hr RNA was collected for qRT-PCR experiments (see above).

CHSY1 allelic skew analyses

Both HEK-293FT cells and T/C-28a2 chondrocytes were screened using Sanger sequencing to identify genotype rs9920291. Sanger sequencing results confirmed preliminary findings using the HEK-293 browser (http://hek293genome.org/v2/) that HEK-293FT cells were heterozygous at rs9920291, unlike T/C-28a2 cells which were homozygous for the reference C allele. Thus, only HEK-293FT cells could be used for allele-specific expression. Next, using the HEK-293 browser with follow-up verification using Sanger sequencing, we identified two heterozygous transcript variants (exon 3 coding variant [rs28364839] and 3’UTR variant [rs11433]).

For allelic skew analyses on untreated HEK-293FT samples, five independent biological replicates were grown and harvested. RNA was isolated separately from each sample using the Trizol Reagent (15596–026, Ambion by Life Technologies, Norwalk, Connecticut) and the RNA Clean and ConcentratorTM-5 Kit (supplied with DNase I, Zymo). Samples were then run on a bioanalyzer to achieve RNA Integrity Numbers greater than 8. These RNA samples were then reverse transcribed using a SuperScript IV First Strand cDNA Synthesis Reaction kit (18090010, Life Technologies) following manufacturer’s recommendations.

cDNA samples were then sent to EpigenDx for allelic skew analysis assay design and execution. SNPs in the coding regions of CHSY1 (rs11433 and rs28364839), were validated by EpigenDx (Hopkinton, Massachusetts). Pyrosequencing for SNP genotyping (PSQ H96A, Qiagen Pyrosequencing) is a real-time sequencing-based DNA analysis that quantitatively determines the genotypes of single or multiple mutations in a single reaction. Briefly, 1 ng of sample cDNA was used for PCR amplification. PCR was performed using 10X PCR buffer (Qiagen Inc., Maryland) at 3.0 mM MgCl2, 200M of each dNTP, 0.2 µM each of the forward and reverse primers (available through EpigenDx), and 0.75 U of HotStar DNA polymerase (Qiagen Inc.), per 30 µl reaction. PCR cycling conditions were: 94°C 15 min; 45 cycles of 94°C 30 s; 60°C 30 s; 72°C 30 s; 72°C 5 min. One of the PCR primer pairs was biotinylated to convert the PCR product to single-stranded DNA sequencing templates using streptavidin beads and the PyroMark Q96 Vacuum Workstation. Ten microliters of the PCR products were bound to streptavidin beads and the single strand containing the biotinylated primer was isolated and combined with a specific sequencing primer (available through EpigenDx). The primed single stranded DNA was sequenced using the Pyrosequencing PSQ96 HS System (Qiagen Pyrosequencing) following the manufacturer’s instructions (Qiagen Pyrosequencing). The genotypes of each sample were analyzed using Q96 software AQ module (Qiagen Pyrosequencing). Pyrosequencing results for each CHSY1 exonic or 3’UTR SNP were used to calculate the allelic ratios in the heterozygous state.

Statistical analysis

For regulatory element transfection experiments, CRISPR-Cas9 deletion experiments, and HOXD13 over-expression experiments, the means ± SEM of multiple independent measurements were calculated. The unpaired two-tailed Student’s t test was used to determine the significance of differences between means. P values smaller than 0.05 (*p<0.05, **p<0.01, ***p<0.001) were considered to be statistical significant.

UniProbe analysis

To find upstream transcription factors (TF) predicted to bind at rs9920291 near CHYS1 we used UniProbe (Hume et al., 2015). UniProbe (http://the_brain.bwh.harvard.edu/uniprobe/about.php) is built on experimental measurements of binding affinities between large numbers of expressed TFs and all possible 8-mer target oligonucleotides (Hume et al., 2015). For two 15 base-pair sequences, each centered at rs9920291 but different only at the C/T variant (Reference [REF] TGCTAAACAAAAATA and Alternate [ALT] TGCTAAATAAAAATA), we imported each sequence separately into the ‘Search for TF Binding Sites’ window on the UniProbe browser (http://the_brain.bwh.harvard.edu/uniprobe/) with the following conditions: Score Threshold: 0.4; Species: Homo sapiens. We acquired 18 TF predictions for REF and 61 TF predictions for ALT. We next imported the results into Supplementary file 7 (sheet 1: REF TGCTAAACAAAAATA and sheet 2: ALT TGCTAAATAAAAATA) and performed an intersection (sheet 3: REF (red) vs. ALT (blue)) to identify those TF-binding preferences that were reduced/gained between the two sequences. For a TF-binding site to be considered reduced or gained, the site must exhibit an enrichment score change of greater than at least 0.10, which corresponded to significant changes in z-score (e.g., Figure 6a). To identify the change in HOXD13 binding affinity, we re-ran UniProbe on the REF sequence but at a lower enrichment score of E >= 0.2. This yielded 341 TF predictions (sheet 4), which were then compared to the 61 TF predictions generated at E >= 0.4 (sheet 5). Finally, to generate the z-score, we downloaded HOXD13 experiment information from UniProbe (http://the_brain.bwh.harvard.edu/uniprobe/browse.php) and identified the corresponding z-score for each 8-mer.

Lists of potential upstream regulators exhibiting marked reduction/gain in binding affinity were then screened using expression and phenotypic data to identify those TFs also expressed or functionally required in growth plates. To carry out this analysis, we used data in VisiGene (http://genome.ucsc.edu/cgi-bin/hgVisigene), Eurexpress (http://www.eurexpress.org/ee/), Genepaint (http://www.genepaint.org/Frameset.html), and the Mouse Genome Informatics expression and phenotypic databases (http://www.informatics.jax.org). HOXD13 met the above criteria. HOXD13 had enrichment scores below the recommended UniProbe threshold of 0.4 for the REF sequence but much higher (above 0.4) for the ALT sequence, and this corresponded to a significant change in z-score (Figure 6a).


  1. 1
  2. 2
  3. 3
  4. 4
    Controlling the false discovery rate: a practical and powerful approach to multiple testing
    1. Y Benjamini
    2. Y Hochberg
    Journal of the Royal Statistical Society 57:289–300.
  5. 5
  6. 6
  7. 7
    ATAC-seq: A method for assaying chromatin accessibility genome-wide
    1. JD Buenrostro
    2. B Wu
    3. HY Chang
    4. WJ Greenleaf
    Current Protocols in Molecular Biology 109:21.29.1–21.2921.
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
    Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk
    1. FR Day
    2. DJ Thompson
    3. H Helgason
    4. DI Chasman
    5. H Finucane
    6. P Sulem
    7. KS Ruth
    8. S Whalen
    9. AK Sarkar
    10. E Albrecht
    11. E Altmaier
    12. M Amini
    13. CM Barbieri
    14. T Boutin
    15. A Campbell
    16. E Demerath
    17. A Giri
    18. C He
    19. JJ Hottenga
    20. R Karlsson
    21. I Kolcic
    22. PR Loh
    23. KL Lunetta
    24. M Mangino
    25. B Marco
    26. G McMahon
    27. SE Medland
    28. IM Nolte
    29. R Noordam
    30. T Nutile
    31. L Paternoster
    32. N Perjakova
    33. E Porcu
    34. LM Rose
    35. KE Schraut
    36. AV Segrè
    37. AV Smith
    38. L Stolk
    39. A Teumer
    40. IL Andrulis
    41. S Bandinelli
    42. MW Beckmann
    43. J Benitez
    44. S Bergmann
    45. M Bochud
    46. E Boerwinkle
    47. SE Bojesen
    48. MK Bolla
    49. JS Brand
    50. H Brauch
    51. H Brenner
    52. L Broer
    53. T Brüning
    54. JE Buring
    55. H Campbell
    56. E Catamo
    57. S Chanock
    58. G Chenevix-Trench
    59. T Corre
    60. FJ Couch
    61. DL Cousminer
    62. A Cox
    63. L Crisponi
    64. K Czene
    65. G Davey Smith
    66. E de Geus
    67. R de Mutsert
    68. I De Vivo
    69. J Dennis
    70. P Devilee
    71. I Dos-Santos-Silva
    72. AM Dunning
    73. JG Eriksson
    74. PA Fasching
    75. L Fernández-Rhodes
    76. L Ferrucci
    77. D Flesch-Janys
    78. L Franke
    79. M Gabrielson
    80. I Gandin
    81. GG Giles
    82. H Grallert
    83. DF Gudbjartsson
    84. P Guénel
    85. P Hall
    86. E Hallberg
    87. U Hamann
    88. TB Harris
    89. CA Hartman
    90. G Heiss
    91. MJ Hooning
    92. JL Hopper
    93. F Hu
    94. DJ Hunter
    95. MA Ikram
    96. HK Im
    97. MR Järvelin
    98. PK Joshi
    99. D Karasik
    100. M Kellis
    101. Z Kutalik
    102. G LaChance
    103. D Lambrechts
    104. C Langenberg
    105. LJ Launer
    106. JSE Laven
    107. S Lenarduzzi
    108. J Li
    109. PA Lind
    110. S Lindstrom
    111. Y Liu
    112. J Luan
    113. R Mägi
    114. A Mannermaa
    115. H Mbarek
    116. MI McCarthy
    117. C Meisinger
    118. T Meitinger
    119. C Menni
    120. A Metspalu
    121. K Michailidou
    122. L Milani
    123. RL Milne
    124. GW Montgomery
    125. AM Mulligan
    126. MA Nalls
    127. P Navarro
    128. H Nevanlinna
    129. DR Nyholt
    130. AJ Oldehinkel
    131. TA O'Mara
    132. S Padmanabhan
    133. A Palotie
    134. N Pedersen
    135. A Peters
    136. J Peto
    137. PDP Pharoah
    138. A Pouta
    139. P Radice
    140. I Rahman
    141. SM Ring
    142. A Robino
    143. FR Rosendaal
    144. I Rudan
    145. R Rueedi
    146. D Ruggiero
    147. CF Sala
    148. MK Schmidt
    149. RA Scott
    150. M Shah
    151. R Sorice
    152. MC Southey
    153. U Sovio
    154. M Stampfer
    155. M Steri
    156. K Strauch
    157. T Tanaka
    158. E Tikkanen
    159. NJ Timpson
    160. M Traglia
    161. T Truong
    162. JP Tyrer
    163. AG Uitterlinden
    164. DRV Edwards
    165. V Vitart
    166. U Völker
    167. P Vollenweider
    168. Q Wang
    169. E Widen
    170. KW van Dijk
    171. G Willemsen
    172. R Winqvist
    173. BHR Wolffenbuttel
    174. JH Zhao
    175. M Zoledziewska
    176. M Zygmunt
    177. BZ Alizadeh
    178. DI Boomsma
    179. M Ciullo
    180. F Cucca
    181. T Esko
    182. N Franceschini
    183. C Gieger
    184. V Gudnason
    185. C Hayward
    186. P Kraft
    187. DA Lawlor
    188. PKE Magnusson
    189. NG Martin
    190. DO Mook-Kanamori
    191. EA Nohr
    192. O Polasek
    193. D Porteous
    194. AL Price
    195. PM Ridker
    196. H Snieder
    197. TD Spector
    198. D Stöckl
    199. D Toniolo
    200. S Ulivi
    201. JA Visser
    202. H Völzke
    203. NJ Wareham
    204. JF Wilson
    205. AB Spurdle
    206. U Thorsteindottir
    207. KS Pollard
    208. DF Easton
    209. JY Tung
    210. J Chang-Claude
    211. D Hinds
    212. A Murray
    213. JM Murabito
    214. K Stefansson
    215. KK Ong
    216. JRB Perry
    217. LifeLines Cohort Study
    218. InterAct Consortium
    219. kConFab/AOCS Investigators
    220. Endometrial Cancer Association Consortium
    221. Ovarian Cancer Association Consortium
    222. PRACTICAL consortium
    Nature Genetics 49:834–841.
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
    Regression Towards mediocrity in hereditary stature
    1. F Galton
    The Journal of the Anthropological Institute of Great Britain and Ireland 15:246–263.
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
    Hundreds of variants clustered in genomic loci and biological pathways affect human height
    1. H Lango Allen
    2. K Estrada
    3. G Lettre
    4. SI Berndt
    5. MN Weedon
    6. F Rivadeneira
    7. CJ Willer
    8. AU Jackson
    9. S Vedantam
    10. S Raychaudhuri
    11. T Ferreira
    12. AR Wood
    13. RJ Weyant
    14. AV Segrè
    15. EK Speliotes
    16. E Wheeler
    17. N Soranzo
    18. JH Park
    19. J Yang
    20. D Gudbjartsson
    21. NL Heard-Costa
    22. JC Randall
    23. L Qi
    24. A Vernon Smith
    25. R Mägi
    26. T Pastinen
    27. L Liang
    28. IM Heid
    29. J Luan
    30. G Thorleifsson
    31. TW Winkler
    32. ME Goddard
    33. K Sin Lo
    34. C Palmer
    35. T Workalemahu
    36. YS Aulchenko
    37. A Johansson
    38. MC Zillikens
    39. MF Feitosa
    40. T Esko
    41. T Johnson
    42. S Ketkar
    43. P Kraft
    44. M Mangino
    45. I Prokopenko
    46. D Absher
    47. E Albrecht
    48. F Ernst
    49. NL Glazer
    50. C Hayward
    51. JJ Hottenga
    52. KB Jacobs
    53. JW Knowles
    54. Z Kutalik
    55. KL Monda
    56. O Polasek
    57. M Preuss
    58. NW Rayner
    59. NR Robertson
    60. V Steinthorsdottir
    61. JP Tyrer
    62. BF Voight
    63. F Wiklund
    64. J Xu
    65. JH Zhao
    66. DR Nyholt
    67. N Pellikka
    68. M Perola
    69. JR Perry
    70. I Surakka
    71. ML Tammesoo
    72. EL Altmaier
    73. N Amin
    74. T Aspelund
    75. T Bhangale
    76. G Boucher
    77. DI Chasman
    78. C Chen
    79. L Coin
    80. MN Cooper
    81. AL Dixon
    82. Q Gibson
    83. E Grundberg
    84. K Hao
    85. M Juhani Junttila
    86. LM Kaplan
    87. J Kettunen
    88. IR König
    89. T Kwan
    90. RW Lawrence
    91. DF Levinson
    92. M Lorentzon
    93. B McKnight
    94. AP Morris
    95. M Müller
    96. J Suh Ngwa
    97. S Purcell
    98. S Rafelt
    99. RM Salem
    100. E Salvi
    101. S Sanna
    102. J Shi
    103. U Sovio
    104. JR Thompson
    105. MC Turchin
    106. L Vandenput
    107. DJ Verlaan
    108. V Vitart
    109. CC White
    110. A Ziegler
    111. P Almgren
    112. AJ Balmforth
    113. H Campbell
    114. L Citterio
    115. A De Grandi
    116. A Dominiczak
    117. J Duan
    118. P Elliott
    119. R Elosua
    120. JG Eriksson
    121. NB Freimer
    122. EJ Geus
    123. N Glorioso
    124. S Haiqing
    125. AL Hartikainen
    126. AS Havulinna
    127. AA Hicks
    128. J Hui
    129. W Igl
    130. T Illig
    131. A Jula
    132. E Kajantie
    133. TO Kilpeläinen
    134. M Koiranen
    135. I Kolcic
    136. S Koskinen
    137. P Kovacs
    138. J Laitinen
    139. J Liu
    140. ML Lokki
    141. A Marusic
    142. A Maschio
    143. T Meitinger
    144. A Mulas
    145. G Paré
    146. AN Parker
    147. JF Peden
    148. A Petersmann
    149. I Pichler
    150. KH Pietiläinen
    151. A Pouta
    152. M Ridderstråle
    153. JI Rotter
    154. JG Sambrook
    155. AR Sanders
    156. CO Schmidt
    157. J Sinisalo
    158. JH Smit
    159. HM Stringham
    160. G Bragi Walters
    161. E Widen
    162. SH Wild
    163. G Willemsen
    164. L Zagato
    165. L Zgaga
    166. P Zitting
    167. H Alavere
    168. M Farrall
    169. WL McArdle
    170. M Nelis
    171. MJ Peters
    172. S Ripatti
    173. JB van Meurs
    174. KK Aben
    175. KG Ardlie
    176. JS Beckmann
    177. JP Beilby
    178. RN Bergman
    179. S Bergmann
    180. FS Collins
    181. D Cusi
    182. M den Heijer
    183. G Eiriksdottir
    184. PV Gejman
    185. AS Hall
    186. A Hamsten
    187. HV Huikuri
    188. C Iribarren
    189. M Kähönen
    190. J Kaprio
    191. S Kathiresan
    192. L Kiemeney
    193. T Kocher
    194. LJ Launer
    195. T Lehtimäki
    196. O Melander
    197. TH Mosley
    198. AW Musk
    199. MS Nieminen
    200. CJ O'Donnell
    201. C Ohlsson
    202. B Oostra
    203. LJ Palmer
    204. O Raitakari
    205. PM Ridker
    206. JD Rioux
    207. A Rissanen
    208. C Rivolta
    209. H Schunkert
    210. AR Shuldiner
    211. DS Siscovick
    212. M Stumvoll
    213. A Tönjes
    214. J Tuomilehto
    215. GJ van Ommen
    216. J Viikari
    217. AC Heath
    218. NG Martin
    219. GW Montgomery
    220. MA Province
    221. M Kayser
    222. AM Arnold
    223. LD Atwood
    224. E Boerwinkle
    225. SJ Chanock
    226. P Deloukas
    227. C Gieger
    228. H Grönberg
    229. P Hall
    230. AT Hattersley
    231. C Hengstenberg
    232. W Hoffman
    233. GM Lathrop
    234. V Salomaa
    235. S Schreiber
    236. M Uda
    237. D Waterworth
    238. AF Wright
    239. TL Assimes
    240. I Barroso
    241. A Hofman
    242. KL Mohlke
    243. DI Boomsma
    244. MJ Caulfield
    245. LA Cupples
    246. J Erdmann
    247. CS Fox
    248. V Gudnason
    249. U Gyllensten
    250. TB Harris
    251. RB Hayes
    252. MR Jarvelin
    253. V Mooser
    254. PB Munroe
    255. WH Ouwehand
    256. BW Penninx
    257. PP Pramstaller
    258. T Quertermous
    259. I Rudan
    260. NJ Samani
    261. TD Spector
    262. H Völzke
    263. H Watkins
    264. JF Wilson
    265. LC Groop
    266. T Haritunians
    267. FB Hu
    268. RC Kaplan
    269. A Metspalu
    270. KE North
    271. D Schlessinger
    272. NJ Wareham
    273. DJ Hunter
    274. JR O'Connell
    275. DP Strachan
    276. HE Wichmann
    277. IB Borecki
    278. CM van Duijn
    279. EE Schadt
    280. U Thorsteinsdottir
    281. L Peltonen
    282. AG Uitterlinden
    283. PM Visscher
    284. N Chatterjee
    285. RJ Loos
    286. M Boehnke
    287. MI McCarthy
    288. E Ingelsson
    289. CM Lindgren
    290. GR Abecasis
    291. K Stefansson
    292. TM Frayling
    293. JN Hirschhorn
    Nature 467:832–838.
  38. 38
  39. 39
  40. 40
  41. 41
    Genetic studies of body mass index yield new insights for obesity biology
    1. AE Locke
    2. B Kahali
    3. SI Berndt
    4. AE Justice
    5. TH Pers
    6. FR Day
    7. C Powell
    8. S Vedantam
    9. ML Buchkovich
    10. J Yang
    11. DC Croteau-Chonka
    12. T Esko
    13. T Fall
    14. T Ferreira
    15. S Gustafsson
    16. Z Kutalik
    17. J Luan
    18. R Mägi
    19. JC Randall
    20. TW Winkler
    21. AR Wood
    22. T Workalemahu
    23. JD Faul
    24. JA Smith
    25. JH Zhao
    26. W Zhao
    27. J Chen
    28. R Fehrmann
    29. ÅK Hedman
    30. J Karjalainen
    31. EM Schmidt
    32. D Absher
    33. N Amin
    34. D Anderson
    35. M Beekman
    36. JL Bolton
    37. JL Bragg-Gresham
    38. S Buyske
    39. A Demirkan
    40. G Deng
    41. GB Ehret
    42. B Feenstra
    43. MF Feitosa
    44. K Fischer
    45. A Goel
    46. J Gong
    47. AU Jackson
    48. S Kanoni
    49. ME Kleber
    50. K Kristiansson
    51. U Lim
    52. V Lotay
    53. M Mangino
    54. IM Leach
    55. C Medina-Gomez
    56. SE Medland
    57. MA Nalls
    58. CD Palmer
    59. D Pasko
    60. S Pechlivanis
    61. MJ Peters
    62. I Prokopenko
    63. D Shungin
    64. A Stančáková
    65. RJ Strawbridge
    66. YJ Sung
    67. T Tanaka
    68. A Teumer
    69. S Trompet
    70. SW van der Laan
    71. J van Setten
    72. JV Van Vliet-Ostaptchouk
    73. Z Wang
    74. L Yengo
    75. W Zhang
    76. A Isaacs
    77. E Albrecht
    78. J Ärnlöv
    79. GM Arscott
    80. AP Attwood
    81. S Bandinelli
    82. A Barrett
    83. IN Bas
    84. C Bellis
    85. AJ Bennett
    86. C Berne
    87. R Blagieva
    88. M Blüher
    89. S Böhringer
    90. LL Bonnycastle
    91. Y Böttcher
    92. HA Boyd
    93. M Bruinenberg
    94. IH Caspersen
    95. YI Chen
    96. R Clarke
    97. EW Daw
    98. AJM de Craen
    99. G Delgado
    100. M Dimitriou
    101. ASF Doney
    102. N Eklund
    103. K Estrada
    104. E Eury
    105. L Folkersen
    106. RM Fraser
    107. ME Garcia
    108. F Geller
    109. V Giedraitis
    110. B Gigante
    111. AS Go
    112. A Golay
    113. AH Goodall
    114. SD Gordon
    115. M Gorski
    116. HJ Grabe
    117. H Grallert
    118. TB Grammer
    119. J Gräßler
    120. H Grönberg
    121. CJ Groves
    122. G Gusto
    123. J Haessler
    124. P Hall
    125. T Haller
    126. G Hallmans
    127. CA Hartman
    128. M Hassinen
    129. C Hayward
    130. NL Heard-Costa
    131. Q Helmer
    132. C Hengstenberg
    133. O Holmen
    134. JJ Hottenga
    135. AL James
    136. JM Jeff
    137. Å Johansson
    138. J Jolley
    139. T Juliusdottir
    140. L Kinnunen
    141. W Koenig
    142. M Koskenvuo
    143. W Kratzer
    144. J Laitinen
    145. C Lamina
    146. K Leander
    147. NR Lee
    148. P Lichtner
    149. L Lind
    150. J Lindström
    151. KS Lo
    152. S Lobbens
    153. R Lorbeer
    154. Y Lu
    155. F Mach
    156. PKE Magnusson
    157. A Mahajan
    158. WL McArdle
    159. S McLachlan
    160. C Menni
    161. S Merger
    162. E Mihailov
    163. L Milani
    164. A Moayyeri
    165. KL Monda
    166. MA Morken
    167. A Mulas
    168. G Müller
    169. M Müller-Nurasyid
    170. AW Musk
    171. R Nagaraja
    172. MM Nöthen
    173. IM Nolte
    174. S Pilz
    175. NW Rayner
    176. F Renstrom
    177. R Rettig
    178. JS Ried
    179. S Ripke
    180. NR Robertson
    181. LM Rose
    182. S Sanna
    183. H Scharnagl
    184. S Scholtens
    185. FR Schumacher
    186. WR Scott
    187. T Seufferlein
    188. J Shi
    189. AV Smith
    190. J Smolonska
    191. AV Stanton
    192. V Steinthorsdottir
    193. K Stirrups
    194. HM Stringham
    195. J Sundström
    196. MA Swertz
    197. AJ Swift
    198. AC Syvänen
    199. ST Tan
    200. BO Tayo
    201. B Thorand
    202. G Thorleifsson
    203. JP Tyrer
    204. HW Uh
    205. L Vandenput
    206. FC Verhulst
    207. SH Vermeulen
    208. N Verweij
    209. JM Vonk
    210. LL Waite
    211. HR Warren
    212. D Waterworth
    213. MN Weedon
    214. LR Wilkens
    215. C Willenborg
    216. T Wilsgaard
    217. MK Wojczynski
    218. A Wong
    219. AF Wright
    220. Q Zhang
    221. EP Brennan
    222. M Choi
    223. Z Dastani
    224. AW Drong
    225. P Eriksson
    226. A Franco-Cereceda
    227. JR Gådin
    228. AG Gharavi
    229. ME Goddard
    230. RE Handsaker
    231. J Huang
    232. F Karpe
    233. S Kathiresan
    234. S Keildson
    235. K Kiryluk
    236. M Kubo
    237. JY Lee
    238. L Liang
    239. RP Lifton
    240. B Ma
    241. SA McCarroll
    242. AJ McKnight
    243. JL Min
    244. MF Moffatt
    245. GW Montgomery
    246. JM Murabito
    247. G Nicholson
    248. DR Nyholt
    249. Y Okada
    250. JRB Perry
    251. R Dorajoo
    252. E Reinmaa
    253. RM Salem
    254. N Sandholm
    255. RA Scott
    256. L Stolk
    257. A Takahashi
    258. T Tanaka
    259. FM van 't Hooft
    260. AAE Vinkhuyzen
    261. HJ Westra
    262. W Zheng
    263. KT Zondervan
    264. AC Heath
    265. D Arveiler
    266. SJL Bakker
    267. J Beilby
    268. RN Bergman
    269. J Blangero
    270. P Bovet
    271. H Campbell
    272. MJ Caulfield
    273. G Cesana
    274. A Chakravarti
    275. DI Chasman
    276. PS Chines
    277. FS Collins
    278. DC Crawford
    279. LA Cupples
    280. D Cusi
    281. J Danesh
    282. U de Faire
    283. HM den Ruijter
    284. AF Dominiczak
    285. R Erbel
    286. J Erdmann
    287. JG Eriksson
    288. M Farrall
    289. SB Felix
    290. E Ferrannini
    291. J Ferrières
    292. I Ford
    293. NG Forouhi
    294. T Forrester
    295. OH Franco
    296. RT Gansevoort
    297. PV Gejman
    298. C Gieger
    299. O Gottesman
    300. V Gudnason
    301. U Gyllensten
    302. AS Hall
    303. TB Harris
    304. AT Hattersley
    305. AA Hicks
    306. LA Hindorff
    307. AD Hingorani
    308. A Hofman
    309. G Homuth
    310. GK Hovingh
    311. SE Humphries
    312. SC Hunt
    313. E Hyppönen
    314. T Illig
    315. KB Jacobs
    316. MR Jarvelin
    317. KH Jöckel
    318. B Johansen
    319. P Jousilahti
    320. JW Jukema
    321. AM Jula
    322. J Kaprio
    323. JJP Kastelein
    324. SM Keinanen-Kiukaanniemi
    325. LA Kiemeney
    326. P Knekt
    327. JS Kooner
    328. C Kooperberg
    329. P Kovacs
    330. AT Kraja
    331. M Kumari
    332. J Kuusisto
    333. TA Lakka
    334. C Langenberg
    335. LL Marchand
    336. T Lehtimäki
    337. V Lyssenko
    338. S Männistö
    339. A Marette
    340. TC Matise
    341. CA McKenzie
    342. B McKnight
    343. FL Moll
    344. AD Morris
    345. AP Morris
    346. JC Murray
    347. M Nelis
    348. C Ohlsson
    349. AJ Oldehinkel
    350. KK Ong
    351. PAF Madden
    352. G Pasterkamp
    353. JF Peden
    354. A Peters
    355. DS Postma
    356. PP Pramstaller
    357. JF Price
    358. L Qi
    359. OT Raitakari
    360. T Rankinen
    361. DC Rao
    362. TK Rice
    363. PM Ridker
    364. JD Rioux
    365. MD Ritchie
    366. I Rudan
    367. V Salomaa
    368. NJ Samani
    369. J Saramies
    370. MA Sarzynski
    371. H Schunkert
    372. PEH Schwarz
    373. P Sever
    374. AR Shuldiner
    375. J Sinisalo
    376. RP Stolk
    377. K Strauch
    378. A Tönjes
    379. DA Trégouët
    380. A Tremblay
    381. E Tremoli
    382. J Virtamo
    383. MC Vohl
    384. U Völker
    385. G Waeber
    386. G Willemsen
    387. JC Witteman
    388. MC Zillikens
    389. LS Adair
    390. P Amouyel
    391. FW Asselbergs
    392. TL Assimes
    393. M Bochud
    394. BO Boehm
    395. E Boerwinkle
    396. SR Bornstein
    397. EP Bottinger
    398. C Bouchard
    399. S Cauchi
    400. JC Chambers
    401. SJ Chanock
    402. RS Cooper
    403. PIW de Bakker
    404. G Dedoussis
    405. L Ferrucci
    406. PW Franks
    407. P Froguel
    408. LC Groop
    409. CA Haiman
    410. A Hamsten
    411. J Hui
    412. DJ Hunter
    413. K Hveem
    414. RC Kaplan
    415. M Kivimaki
    416. D Kuh
    417. M Laakso
    418. Y Liu
    419. NG Martin
    420. W März
    421. M Melbye
    422. A Metspalu
    423. S Moebus
    424. PB Munroe
    425. I Njølstad
    426. BA Oostra
    427. CNA Palmer
    428. NL Pedersen
    429. M Perola
    430. L Pérusse
    431. U Peters
    432. C Power
    433. T Quertermous
    434. R Rauramaa
    435. F Rivadeneira
    436. TE Saaristo
    437. D Saleheen
    438. N Sattar
    439. EE Schadt
    440. D Schlessinger
    441. PE Slagboom
    442. H Snieder
    443. TD Spector
    444. U Thorsteinsdottir
    445. M Stumvoll
    446. J Tuomilehto
    447. AG Uitterlinden
    448. M Uusitupa
    449. P van der Harst
    450. M Walker
    451. H Wallaschofski
    452. NJ Wareham
    453. H Watkins
    454. DR Weir
    455. HE Wichmann
    456. JF Wilson
    457. P Zanen
    458. IB Borecki
    459. P Deloukas
    460. CS Fox
    461. IM Heid
    462. JR O'Connell
    463. DP Strachan
    464. K Stefansson
    465. CM van Duijn
    466. GR Abecasis
    467. L Franke
    468. TM Frayling
    469. MI McCarthy
    470. PM Visscher
    471. A Scherag
    472. CJ Willer
    473. M Boehnke
    474. KL Mohlke
    475. CM Lindgren
    476. JS Beckmann
    477. I Barroso
    478. KE North
    479. E Ingelsson
    480. JN Hirschhorn
    481. RJF Loos
    482. EK Speliotes
    483. LifeLines Cohort Study
    484. ADIPOGen Consortium
    485. AGEN-BMI Working Group
    486. CARDIOGRAMplusC4D Consortium
    487. CKDGen Consortium
    488. GLGC
    489. ICBP
    490. MAGIC Investigators
    491. MuTHER Consortium
    492. MIGen Consortium
    493. PAGE Consortium
    494. ReproGen Consortium
    495. GENIE Consortium
    496. International Endogene Consortium
    Nature 518:197–206.
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
    Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes
    1. AP Morris
    2. BF Voight
    3. TM Teslovich
    4. T Ferreira
    5. AV Segrè
    6. V Steinthorsdottir
    7. RJ Strawbridge
    8. H Khan
    9. H Grallert
    10. A Mahajan
    11. I Prokopenko
    12. HM Kang
    13. C Dina
    14. T Esko
    15. RM Fraser
    16. S Kanoni
    17. A Kumar
    18. V Lagou
    19. C Langenberg
    20. J Luan
    21. CM Lindgren
    22. M Müller-Nurasyid
    23. S Pechlivanis
    24. NW Rayner
    25. LJ Scott
    26. S Wiltshire
    27. L Yengo
    28. L Kinnunen
    29. EJ Rossin
    30. S Raychaudhuri
    31. AD Johnson
    32. AS Dimas
    33. RJ Loos
    34. S Vedantam
    35. H Chen
    36. JC Florez
    37. C Fox
    38. CT Liu
    39. D Rybin
    40. DJ Couper
    41. WH Kao
    42. M Li
    43. MC Cornelis
    44. P Kraft
    45. Q Sun
    46. RM van Dam
    47. HM Stringham
    48. PS Chines
    49. K Fischer
    50. P Fontanillas
    51. OL Holmen
    52. SE Hunt
    53. AU Jackson
    54. A Kong
    55. R Lawrence
    56. J Meyer
    57. JR Perry
    58. CG Platou
    59. S Potter
    60. E Rehnberg
    61. N Robertson
    62. S Sivapalaratnam
    63. A Stančáková
    64. K Stirrups
    65. G Thorleifsson
    66. E Tikkanen
    67. AR Wood
    68. P Almgren
    69. M Atalay
    70. R Benediktsson
    71. LL Bonnycastle
    72. N Burtt
    73. J Carey
    74. G Charpentier
    75. AT Crenshaw
    76. AS Doney
    77. M Dorkhan
    78. S Edkins
    79. V Emilsson
    80. E Eury
    81. T Forsen
    82. K Gertow
    83. B Gigante
    84. GB Grant
    85. CJ Groves
    86. C Guiducci
    87. C Herder
    88. AB Hreidarsson
    89. J Hui
    90. A James
    91. A Jonsson
    92. W Rathmann
    93. N Klopp
    94. J Kravic
    95. K Krjutškov
    96. C Langford
    97. K Leander
    98. E Lindholm
    99. S Lobbens
    100. S Männistö
    101. G Mirza
    102. TW Mühleisen
    103. B Musk
    104. M Parkin
    105. L Rallidis
    106. J Saramies
    107. B Sennblad
    108. S Shah
    109. G Sigurðsson
    110. A Silveira
    111. G Steinbach
    112. B Thorand
    113. J Trakalo
    114. F Veglia
    115. R Wennauer
    116. W Winckler
    117. D Zabaneh
    118. H Campbell
    119. C van Duijn
    120. AG Uitterlinden
    121. A Hofman
    122. E Sijbrands
    123. GR Abecasis
    124. KR Owen
    125. E Zeggini
    126. MD Trip
    127. NG Forouhi
    128. AC Syvänen
    129. JG Eriksson
    130. L Peltonen
    131. MM Nöthen
    132. B Balkau
    133. CN Palmer
    134. V Lyssenko
    135. T Tuomi
    136. B Isomaa
    137. DJ Hunter
    138. L Qi
    139. AR Shuldiner
    140. M Roden
    141. I Barroso
    142. T Wilsgaard
    143. J Beilby
    144. K Hovingh
    145. JF Price
    146. JF Wilson
    147. R Rauramaa
    148. TA Lakka
    149. L Lind
    150. G Dedoussis
    151. I Njølstad
    152. NL Pedersen
    153. KT Khaw
    154. NJ Wareham
    155. SM Keinanen-Kiukaanniemi
    156. TE Saaristo
    157. E Korpi-Hyövälti
    158. J Saltevo
    159. M Laakso
    160. J Kuusisto
    161. A Metspalu
    162. FS Collins
    163. KL Mohlke
    164. RN Bergman
    165. J Tuomilehto
    166. BO Boehm
    167. C Gieger
    168. K Hveem
    169. S Cauchi
    170. P Froguel
    171. D Baldassarre
    172. E Tremoli
    173. SE Humphries
    174. D Saleheen
    175. J Danesh
    176. E Ingelsson
    177. S Ripatti
    178. V Salomaa
    179. R Erbel
    180. KH Jöckel
    181. S Moebus
    182. A Peters
    183. T Illig
    184. U de Faire
    185. A Hamsten
    186. AD Morris
    187. PJ Donnelly
    188. TM Frayling
    189. AT Hattersley
    190. E Boerwinkle
    191. O Melander
    192. S Kathiresan
    193. PM Nilsson
    194. P Deloukas
    195. U Thorsteinsdottir
    196. LC Groop
    197. K Stefansson
    198. F Hu
    199. JS Pankow
    200. J Dupuis
    201. JB Meigs
    202. D Altshuler
    203. M Boehnke
    204. MI McCarthy
    205. Wellcome Trust Case Control Consortium
    206. Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators
    207. Genetic Investigation of ANthropometric Traits (GIANT) Consortium
    208. Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium
    209. South Asian Type 2 Diabetes (SAT2D) Consortium
    210. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium
    Nature Genetics 44:981–990.
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
    Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
    1. H Schunkert
    2. IR König
    3. S Kathiresan
    4. MP Reilly
    5. TL Assimes
    6. H Holm
    7. M Preuss
    8. AF Stewart
    9. M Barbalic
    10. C Gieger
    11. D Absher
    12. Z Aherrahrou
    13. H Allayee
    14. D Altshuler
    15. SS Anand
    16. K Andersen
    17. JL Anderson
    18. D Ardissino
    19. SG Ball
    20. AJ Balmforth
    21. TA Barnes
    22. DM Becker
    23. LC Becker
    24. K Berger
    25. JC Bis
    26. SM Boekholdt
    27. E Boerwinkle
    28. PS Braund
    29. MJ Brown
    30. MS Burnett
    31. I Buysschaert
    32. JF Carlquist
    33. L Chen
    34. S Cichon
    35. V Codd
    36. RW Davies
    37. G Dedoussis
    38. A Dehghan
    39. S Demissie
    40. JM Devaney
    41. P Diemert
    42. R Do
    43. A Doering
    44. S Eifert
    45. NE Mokhtari
    46. SG Ellis
    47. R Elosua
    48. JC Engert
    49. SE Epstein
    50. U de Faire
    51. M Fischer
    52. AR Folsom
    53. J Freyer
    54. B Gigante
    55. D Girelli
    56. S Gretarsdottir
    57. V Gudnason
    58. JR Gulcher
    59. E Halperin
    60. N Hammond
    61. SL Hazen
    62. A Hofman
    63. BD Horne
    64. T Illig
    65. C Iribarren
    66. GT Jones
    67. JW Jukema
    68. MA Kaiser
    69. LM Kaplan
    70. JJ Kastelein
    71. KT Khaw
    72. JW Knowles
    73. G Kolovou
    74. A Kong
    75. R Laaksonen
    76. D Lambrechts
    77. K Leander
    78. G Lettre
    79. M Li
    80. W Lieb
    81. C Loley
    82. AJ Lotery
    83. PM Mannucci
    84. S Maouche
    85. N Martinelli
    86. PP McKeown
    87. C Meisinger
    88. T Meitinger
    89. O Melander
    90. PA Merlini
    91. V Mooser
    92. T Morgan
    93. TW Mühleisen
    94. JB Muhlestein
    95. T Münzel
    96. K Musunuru
    97. J Nahrstaedt
    98. CP Nelson
    99. MM Nöthen
    100. O Olivieri
    101. RS Patel
    102. CC Patterson
    103. A Peters
    104. F Peyvandi
    105. L Qu
    106. AA Quyyumi
    107. DJ Rader
    108. LS Rallidis
    109. C Rice
    110. FR Rosendaal
    111. D Rubin
    112. V Salomaa
    113. ML Sampietro
    114. MS Sandhu
    115. E Schadt
    116. A Schäfer
    117. A Schillert
    118. S Schreiber
    119. J Schrezenmeir
    120. SM Schwartz
    121. DS Siscovick
    122. M Sivananthan
    123. S Sivapalaratnam
    124. A Smith
    125. TB Smith
    126. JD Snoep
    127. N Soranzo
    128. JA Spertus
    129. K Stark
    130. K Stirrups
    131. M Stoll
    132. WH Tang
    133. S Tennstedt
    134. G Thorgeirsson
    135. G Thorleifsson
    136. M Tomaszewski
    137. AG Uitterlinden
    138. AM van Rij
    139. BF Voight
    140. NJ Wareham
    141. GA Wells
    142. HE Wichmann
    143. PS Wild
    144. C Willenborg
    145. JC Witteman
    146. BJ Wright
    147. S Ye
    148. T Zeller
    149. A Ziegler
    150. F Cambien
    151. AH Goodall
    152. LA Cupples
    153. T Quertermous
    154. W März
    155. C Hengstenberg
    156. S Blankenberg
    157. WH Ouwehand
    158. AS Hall
    159. P Deloukas
    160. JR Thompson
    161. K Stefansson
    162. R Roberts
    163. U Thorsteinsdottir
    164. CJ O'Donnell
    165. R McPherson
    166. J Erdmann
    167. NJ Samani
    168. Cardiogenics
    169. CARDIoGRAM Consortium
    Nature Genetics 43:333–338.
  59. 59
    Requirement for Pbx1 in skeletal patterning and programming chondrocyte proliferation and differentiation
    1. L Selleri
    2. MJ Depew
    3. Y Jacobs
    4. SK Chanda
    5. KY Tsang
    6. KS Cheah
    7. JL Rubenstein
    8. S O'Gorman
    9. ML Cleary
    Development 128:3543–3557.
  60. 60
  61. 61